AU Patent

AU2018218310B2 — Rescue treatment of post operative nausea and vomiting

Assigned to Acacia Pharma Ltd · Expires 2024-02-15 · 2y expired

What this patent protects

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.

USPTO Abstract

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018218310B2
Jurisdiction
AU
Classification
—
Expires
2024-02-15
Drug substance claim
No
Drug product claim
No
Assignee
Acacia Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.